The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Distinct requirements for Ras oncogenesis in human versus mouse cells
Open accessAbstract
The spectrum of tumors associated with oncogenic Ras in humans often differs from those in mice either treated with carcinogens or engineered to sporadically express oncogenic Ras, suggesting that the mechanism of Ras transformation may be different in humans. Ras stimulates primarily three main classes of effector proteins, Rafs, PI3-kinase, and RalGEFs, with Raf generally being the most potent at transforming murine cells. Using oncogenic Ras mutants that activate single effectors as well as constitutively active effectors, we find that the RalGEF, and not the Raf or PI3-kinase pathway, is sufficient for Ras transformation in human cells. Thus, oncogenic Ras may transform murine and human cells by distinct mechanisms, and the RalGEF pathway—previously deemed to play a secondary role in Ras transformation—could represent a new target for anti-cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“One drawback of studying Ras-induced transformation in human cells is that ectopic expression of Ras causes cellular senescence in primary human cells (Serrano et al. 1997).”
Backgroundras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Extension of Life-Span by Introduction of Telomerase into Normal Human Cells
Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C.-P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., & Wright, W. E. (1998) · Science · doi:10.1126/science.279.5349.349 · Cited by 4,975
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
A survey of telomerase activity in human cancer
Shay, J. W., & Bacchetti, S. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00062-2 · Cited by 2,794 · cited 2×
“…hTERT is the catalytic subunit of telomerase (Nakamura and Cech 1998), which is essential to immortalize human cells (Bodnar et al. 1998; Counter et al. 1998; Vaziri and Benchimol 1998) and is illegitimately activated to restore telomerase activity in 85% of human cancers (Shay and Bacchetti 1997).”
BackgroundSouthern, P. J., & Berg, P. R. (1982) · PubMed · Cited by 2,740
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Self-citationMorgenstern, J. P., & Land, H. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.12.3587 · Cited by 2,101
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,006
Cowley, S. (1994) · Cell · doi:10.1016/0092-8674(94)90133-3 · Cited by 1,966
Effects of an Rb mutation in the mouse
Jacks, T., Fazeli, A., Schmitt, E. M., Bronson, R. T., Goodell, M. A., & Weinberg, R. A. (1992) · Nature · doi:10.1038/359295a0 · Cited by 1,755
Transformation of Mammalian Cells by Constitutively Active MAP Kinase Kinase
Mansour, S. J., Matten, W. T., Hermann, A. S., Candia, J. M., Rong, S., Fukasawa, K., Vande Woude, G. F., & Ahn, N. G. (1994) · Science · doi:10.1126/science.8052857 · Cited by 1,353
Raf-1 activates MAP kinase-kinase
Kyriakis, J. M., App, H., Zhang, X.-F., Banerjee, P., Brautigan, D. L., Rapp, U. R., & Avruch, J. (1992) · Nature · doi:10.1038/358417a0 · Cited by 1,283
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179
Rodriguez-Viciana, P., Warne, P. H., Khwaja, A., Marte, B. M., Pappin, D., Das, P., Waterfield, M. D., Ridley, A., & Downward, J. (1997) · Cell · doi:10.1016/s0092-8674(00)80226-3 · Cited by 1,061
Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
Leevers, S. J., Paterson, H. F., & Marshall, C. J. (1994) · Nature · doi:10.1038/369411a0 · Cited by 1,011
Vaziri, H., & Benchimol, S. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70109-5 · Cited by 1,003
Activation of Raf as a Result of Recruitment to the Plasma Membrane
Stokoe, D., Macdonald, S. G., Cadwallader, K., Symons, M., & Hancock, J. F. (1994) · Science · doi:10.1126/science.7811320 · Cited by 976
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., et al. (1999) · Nature Medicine · doi:10.1038/10533 · Cited by 970
An essential role for Rac in Ras transformation
Qiu, R.-G., Chen, J., Kirn, D., McCormick, F., & Symons, M. (1995) · Nature · doi:10.1038/374457a0 · Cited by 882
Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
Elenbaas, B., Spirio, L., Koerner, F., Fleming, M. D., Zimonjic, D. B., Donaher, J. L., Popescu, N. C., Hahn, W. C., & Weinberg, R. A. (2001) · Genes & Development · doi:10.1101/gad.828901 · Cited by 878
Zarbl, H., Sukumar, S., Arthur, A. V., Martin-Zanca, D., & Barbacid, M. (1985) · Nature · doi:10.1038/315382a0 · Cited by 820
Understanding Ras: ‘it ain’t over ’til it’s over’
Shields, J. M., Pruitt, K., McFall, A., Shaub, A., & Der, C. J. (2000) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01740-2 · Cited by 780
Self-citationTumour predisposition in mice heterozygous for a targeted mutation in Nf1
Jacks, T., Shih, T. S., Schmitt, E. M., Bronson, R. T., Bernards, A., & Weinberg, R. A. (1994) · Nature Genetics · doi:10.1038/ng0794-353 · Cited by 778
Hoshino, R., Chatani, Y., Yamori, T., Tsuruo, T., Oka, H., Yoshida, O., Shimada, Y., Ari-i, S., Wada, H., Fujimoto, J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202367 · Cited by 691
Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation
Khosravi-Far, R., Solski, P. A., Clark, G. J., Kinch, M. S., & Der, C. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.11.6443 · Cited by 683
Self-citationDissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization
Counter, C. M., Hahn, W. C., Wei, W., Caddle, S. D., Beijersbergen, R. L., Lansdorp, P. M., Sedivy, J. M., & Weinberg, R. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14723 · Cited by 649
Self-citationMultiple ras functions can contribute to mammalian cell transformation
White, M. A., Nicolette, C., Minden, A., Polverino, A., Aelst, L. V., Karin, M., & Wigler, M. H. (1995) · Cell · doi:10.1016/0092-8674(95)90507-3 · Cited by 649
Enumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation
Hahn, W. C., Dessain, S. K., Brooks, M. W., King, J. E., Elenbaas, B., Sabatini, D. M., DeCaprio, J. A., & Weinberg, R. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2111-2123.2002 · Cited by 612
Pallas, D. C., Shahrik, L. K., Martin, B. L., Jaspers, S., Miller, T. B., Brautigan, D. L., & Roberts, T. M. (1990) · Cell · doi:10.1016/0092-8674(90)90726-u · Cited by 573
Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation.
Rodriguez-Viciana, P., Warne, P. H., Vanhaesebroeck, B., Waterfield, M. D., & Downward, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00602.x · Cited by 566
Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1.
Alessi, D. R., Saito, Y., Campbell, D. G., Cohen, P., Sithanandam, G., Rapp, U., Ashworth, A., Marshall, C. J., & Cowley, S. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06424.x · Cited by 559
Raf-1 protein kinase is required for growth of induced NIH/3T3 cells
Kolch, W., Heidecker, G., Lloyd, P., & Rapp, U. R. (1991) · Nature · doi:10.1038/349426a0 · Cited by 474
Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., & Fabbro, D. (1996) · Nature Medicine · doi:10.1038/nm0696-668 · Cited by 447
PIK3CA as an oncogene in cervical cancer
Ma, Y.-Y., Wei, S.-J., Lin, Y.-C., Lung, J.-C., Chang, T.-C., Whang-Peng, J., Liu, J. M., Yang, D.-M., Yang, W. K., & Shen, C.-Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203597 · Cited by 434
Bergsagel, D. J., Finegold, M. J., Butel, J. S., Kupsky, W. J., & Garcea, R. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204093261504 · Cited by 415
Tumors associated with p53 germline mutations: a synopsis of 91 families.
Kleihues, P., Schäuble, B., Hausen, A. Z., Estève, J., & Ohgaki, H. (1997) · Europe PMC (PubMed Central) · Cited by 411
Simian virus 40-like DNA sequences in human pleural mesothelioma.
Carbone, M., Pass, H. I., Rizzo, P., Marinetti, M. R., Muzio, M. D., Mew, D., Levine, A. S., & Procopio, A. D. (1994) · PubMed · Cited by 397
Legius, E., Marchuk, D. A., Collins, F. S., & Glover, T. W. (1993) · Nature Genetics · doi:10.1038/ng0293-122 · Cited by 391
Genetic Origin of Mutations Predisposing to Retinoblastoma
Cavenee, W. K., Hansen, M. F., Nordenskjold, M., Kock, E., Maumenee, I., Squire, J. A., Phillips, R. A., & Gallie, B. L. (1985) · Science · doi:10.1126/science.3983638 · Cited by 359
Khosravi-Far, R., White, M. A., Westwick, J. K., Solski, P. A., Chrzanowska-Wodnicka, M., Van Aelst, L., Wigler, M. H., & Der, C. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3923 · Cited by 343
Self-citationGreenberg, R. A., Allsopp, R. C., Chin, L., Morin, G. B., & DePinho, R. A. (1998) · Oncogene · doi:10.1038/sj.onc.1201933 · Cited by 338
Urano, T., Emkey, R., & Feig, L. A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00416.x · Cited by 331
Development of anticancer drugs targeting the MAP kinase pathway
Sebolt-Leopold, J. S. (2000) · Oncogene · doi:10.1038/sj.onc.1204083 · Cited by 320
Mutants of SV40 with an altered small t protein are reduced in their ability to transform cells
Sleigh, M. (1978) · Cell · doi:10.1016/0092-8674(78)90303-3 · Cited by 275
Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene
Colman, S. D., Williams, C. A., & Wallace, M. R. (1995) · Nature Genetics · doi:10.1038/ng0995-90 · Cited by 252
Cifone, M. A., & Fidler, I. J. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.2.1039 · Cited by 243
White, M. A., Vale, T., Camonis, J. H., Schaefer, E., & Wigler, M. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.28.16439 · Cited by 240
Martini, F., Iaccheri, L., Lazzarin, L., Carinci, P., Corallini, A., Gerosa, M. A., Iuzzolino, P., Barbanti-Brodano, G., & Tognon, M. G. (1996) · PubMed · Cited by 205
PI3-kinase inhibition: a target for drug development?
Stein, R. C., & Waterfield, M. D. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(00)01770-6 · Cited by 192
Westwick, J. K., Cox, A. D., Der, C. J., Cobb, M. H., Hibi, M., Karin, M., & Brenner, D. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.6030 · Cited by 187
Self-citationN-Terminal Domains of the Human Telomerase Catalytic Subunit Required for Enzyme Activity in Vivo
Armbruster, B. N., Banik, S. S. R., Guo, C., Smith, A. C., & Counter, C. M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.22.7775-7786.2001 · Cited by 183
Self-citationInteractions between SV40 large‐tumor antigen and the growth suppressor proteins pRB and p53
Ludlow, J. W. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344486 · Cited by 178
Stimulation of gene induction and cell growth by the Ras effector Rlf
Wolthuis, R. M. F. (1997) · The EMBO Journal · doi:10.1093/emboj/16.22.6748 · Cited by 163
Ward, Y., Wang, W., Woodhouse, E., Linnoila, I., Liotta, L., & Kelly, K. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.17.5958-5969.2001 · Cited by 161
Schaap, D., van der Wal, J., Howe, L. R., Marshall, C. J., & van Blitterswijk, W. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80719-4 · Cited by 160
Ras caught in another affair: the exchange factors for Ral
Wolthuis, R. M. F., & Bos, J. L. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80016-1 · Cited by 156
Oldham, S., Clark, G. J., Gangarosa, L. M., Coffey, R. J., & Der, C. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.14.6924 · Cited by 142
Self-citationA genetically tractable model of human glioma formation.
Rich, J. N., Guo, C., McLendon, R. E., Bigner, D. D., Wang, X., & Counter, C. M. (2001) · PubMed · Cited by 141
Self-citationLinnemann, T., Geyer, M., Jaitner, B. K., Block, C., Kalbitzer, H. R., Wittinghofer, A., & Herrmann, C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.19.13556 · Cited by 135
Stevenson, J. P., Yao, K.-S., Gallagher, M., Friedland, D. P., Mitchell, E. P., Cassella, A., Monia, B. P., Kwoh, T. J., Yu, R. Z., Holmlund, J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2227 · Cited by 129
Telomerase activity in normal and malignant murine tissues.
Chadéneau, C., Siegel, P. M., Cb, H., Wj, M., & Bacchetti, S. (1995) · PubMed · Cited by 127
Cunningham, C. C., Holmlund, J., Schiller, J. H., Geary, R. S., Kwoh, T. J., Dorr, A., & Nemunaitis, J. J. (2000) · PubMed · Cited by 126
Protein binding and signaling properties of RIN1 suggest a unique effector function
Han, L., Wong, D., Dhaka, A., Afar, D., White, M. A., Xie, W., Herschman, H. R., Witte, O. N., & Colicelli, J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.4954 · Cited by 114
Lu, Z., Hornia, A., Joseph, T. W., Sukezane, T., Frankel, P., Zhong, M., Bychenok, S., Xu, L., Feig, L. A., & Foster, D. A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.2.462-467.2000 · Cited by 105
RAS inhibitors: potential for cancer therapeutics
Kloog, Y., & Cox, A. D. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(00)01789-5 · Cited by 89
Goi, T., Rusanescu, G., Urano, T., & Feig, L. A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1731 · Cited by 86
Rebhun, J. F., Chen, H., & Quilliam, L. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000085200 · Cited by 84
A Novel RalGEF-like Protein, RGL3, as a Candidate Effector for Rit and Ras
Shao, H., & Andres, D. (2000) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)61461-4 · Cited by 78
Inhibition of H-Ras transformation by the PTEN/MMAC1/TEP1 tumor suppressor gene
Tolkacheva, T., & Chan, A. M.-L. (2000) · Oncogene · doi:10.1038/sj.onc.1203331 · Cited by 64
Dissociation of anchorage independence from tumorigenicity in human cell hybrids
Stanbridge, E. J., & Wilkinson, J. (1980) · International Journal of Cancer · doi:10.1002/ijc.2910260102 · Cited by 60
D’Adamo, D. R., Novick, S. C., Kahn, J. M., Leonardi, P., & Pellicer, À. (1997) · Oncogene · doi:10.1038/sj.onc.1200950 · Cited by 59
Involvement of Phosphatidylinositol 3-Kinase, but Not RalGDS, in TC21/R-Ras2-mediated Transformation
Murphy, G. A., Graham, S. M., Morita, S., Reks, S. E., Rogers-Graham, K., Vojtek, A. B., Kelley, G. G., & Der, C. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109059200 · Cited by 58
Self-citationRalGEF2, a Pleckstrin Homology Domain Containing Guanine Nucleotide Exchange Factor for Ral
de Bruyn, K. M. T., de Rooij, J., Wolthuis, R. M. F., Rehmann, H., Wesenbeek, J., Cool, R. H., Wittinghofer, A., & Bos, J. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001160200 · Cited by 56
Guanine nucleotide binding properties of the mammalian RalA protein produced in Escherichia coli.
Frech, M., Schlichting, I., Wittinghofer, A., & Chardin, P. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39333-0 · Cited by 53
A Role for RalGDS and a Novel Ras Effector in the Ras-mediated Inhibition of Skeletal Myogenesis
Ramocki, M. B., White, M. A., Konieczny, S. F., & Taparowsky, E. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.28.17696 · Cited by 49
Guo, C., Geverd, D. A., Liao, R. P., Hamad, N. M., Counter, C. M., & PRICE, D. T. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)66045-4 · Cited by 30
Self-citationRas effectors: Buying shares in Ras plc
Cullen, P. J. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00189-0 · Cited by 28
Sablowski, R. W. M., & Meyerowitz, E. M. (1998) · Cell · doi:10.1016/s0092-8674(00)80950-2 · Cited by 20
(1998) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(19980701)83:1 · Cited by 3
Cited by
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
Self-citationDolma, S., Lessnick, S. L., Hahn, W. C., & Stockwell, B. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00050-3 · Cited by 1,446
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
Metadata
- Authors
- Hamad, N. M., Elconin, J. H., Karnoub, A. E., Bai, W., Rich, J. N., Abraham, R. T., Der, C. J., & Counter, C. M.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2002-08-15
- Volume
- 16
- Issue
- 16
- Pages
- 2045-2057
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W4299676702
- Cited by
- 431
- References
- 80
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.